CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a ...
IFLScience needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time.
TOKYO--(BUSINESS WIRE)--SanBio Co., Ltd. (headquarters: Chuo-ku, Tokyo, Representative Director and President: Keita Mori, hereafter “SanBio”) hereby announces that it has obtained new analytical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback